Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatm...
July 31 2020 - 9:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
preliminary results for the first cohort of 223 subjects from its
ongoing Phase 2 long-term safety study evaluating ARQ-151 (topical
roflumilast cream) 0.3% as a potential once-daily chronic topical
treatment for plaque psoriasis. Arcutis now expects to have topline
data for the full study population of 332 subjects from both
cohorts in the first quarter of 2021.
The first cohort of the long-term safety study
includes subjects who elected to continue open-label treatment
following their participation in the double-blind, randomized Phase
2b study of roflumilast cream in plaque psoriasis, the results from
which were recently published in the New England Journal of
Medicine. In this group of subjects, roflumilast cream 0.3%
applied once daily for up to a total of 52 to 64 weeks demonstrated
favorable safety and tolerability over the long-term treatment
period, consistent with what was seen in the parent Phase 2b
study. At 52 to 64 weeks of treatment, 44% of subjects had an
Investigator Global Assessment (IGA) of clear or almost clear,
compared to 38% of subjects at 12 weeks of treatment with ARQ-151
0.3% in the parent Phase 2b study. Additionally, of the
subjects in the parent Phase 2b study who received ARQ-151 0.3%,
attained an IGA of clear or almost clear at 12 weeks, and continued
on treatment in the long-term safety study, 68% had an IGA of clear
or almost clear at the end of 64 weeks of treatment. Subjects who
had received vehicle in the parent Phase 2b study but then received
active treatment in the long-term safety study achieved IGA of
clear or almost clear at a similar percentage and in a similar time
course as subjects who received active treatment in the parent
study. Of the 223 subjects included in this analysis, 73%
have completed the full 52 weeks of open label treatment.
“While these data are preliminary, we are
delighted with the results from this first group of subjects to
receive long-term treatment with roflumilast cream, which support
our belief that roflumilast cream, unlike high potency steroids,
can be used chronically,” said Frank Watanabe, Arcutis’ President
and Chief Executive Officer. “While we are still awaiting the
full results from this study, we are encouraged by these early
indications that the long-term efficacy and tolerability seem to be
consistent with the results seen in the parent study. For far too
long, patients and their dermatologists have been forced to make
trade-offs in efficacy, safety, and tolerability due to the
significant shortcomings of existing topical treatments for
psoriasis. We continue to believe that topical roflumilast
has the potential to offer an ideal combination of efficacy
comparable to a high potency steroid, the ability to use the drug
chronically in any anatomical area, and a favorable safety and
tolerability profile. We are hopeful that topical roflumilast, if
approved, will help dermatologists and their patients to overcome
these difficult clinical compromises.”
The roflumilast cream long-term safety study is
a Phase 2, multi-center, open label study of the long-term safety
and efficacy of roflumilast cream 0.3% in adult subjects with
chronic plaque psoriasis involving up to 25% total body surface
area (BSA), evaluated in two ongoing cohorts: subjects who
completed the ARQ-151-201 Phase 2b, randomized, controlled trial;
and previously untreated subjects. The subjects apply roflumilast
cream 0.3% once daily for 52 weeks at home. Some subjects who
entered this long-term study after completing the parent Phase 2b
study will therefore have received up to 64 weeks of total
treatment with topical roflumilast (12 weeks in the parent Phase 2b
study and 52 weeks in the long-term safety study). Periodic clinic
visits include assessments for clinical safety, application site
reactions, and disease improvement or progression. The
primary outcome measures of the study are the occurrence of
treatment emergent adverse events and the occurrence of serious
adverse events. Full results from this study are expected in
the first quarter of 2021.
Roflumilast cream is a once-daily topical cream
formulation of a highly potent and selective PDE4 inhibitor
(roflumilast). Roflumilast has been approved by the U.S. Food and
Drug Administration (FDA) for systemic treatment to reduce the risk
of exacerbations of chronic obstructive pulmonary disease (COPD)
since 2011. Roflumilast has shown greater potency (25-to 300-fold)
than the two other FDA-approvedPDE4 inhibitors. PDE4 is an
intracellular enzyme that increases the production of
pro-inflammatory mediators and decreases production of
anti-inflammatory mediators and has been implicated in a wide range
of inflammatory diseases including psoriasis, eczema, and COPD.
PDE4 is an established target in dermatology, and other PDE4
inhibitors have been approved by the FDA for the topical treatment
of atopic dermatitis or the systemic treatment of plaque
psoriasis.
About PsoriasisPsoriasis is a
common, non-contagious, immune disease that affects approximately
8.6 million patients in the United States and requires chronic
treatment. About 90% of psoriasis cases are plaque psoriasis,
which is characterized by raised, red areas of skin covered with a
silver or white layer of scale. Psoriatic plaques can appear
on any area of the body, but most often appear on the scalp, knees,
elbows, trunk, and limbs, and the plaques are often itchy and
sometimes painful. Plaques in certain anatomical areas
present particular treatment challenges, including the face, elbows
and knees, scalp, and intertriginous regions such as the groin,
axillae and inframammary areas.
About Arcutis - Bioscience,
applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is
a late-stage biopharmaceutical company focused on developing and
commercializing treatments for unmet needs in immune-mediated
dermatological diseases and conditions, or
immuno-dermatology. The company is leveraging recent advances
in immunology and inflammation to develop differentiated therapies
against biologically validated targets to solve persistent
treatment challenges in serious diseases of the skin. Arcutis’
robust pipeline includes four novel drug candidates currently in
development for a range of inflammatory dermatological conditions.
The company’s lead product candidate, topical roflumilast, has the
potential to revitalize the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic
dermatitis. For more information, visit
https://www.arcutis.com or follow the company on LinkedIn and
Twitter.
Forward Looking StatementsThis
press release contains "forward-looking" statements, including,
among others, statements regarding the potential of roflumilast
cream to address the unmet needs in the topical treatment of
psoriasis; the potential safety and efficacy of roflumilast cream;
and the timing of clinical data readouts. These statements involve
substantial known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements and you should not place undue reliance on our
forward-looking statements. Risks and uncertainties that may cause
our actual results to differ include risks inherent in the clinical
development process and regulatory approval process, the timing of
regulatory filings, and our ability to defend our intellectual
property. For a further description of the risks and uncertainties
applicable to our business, see the "Risk Factors" section of our
Form 10-Q filed with U.S. Securities and Exchange Commission (SEC)
on May 12, 2020, as well as any subsequent filings with the SEC. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.
Contact:Heather Rowe Armstrong Vice President,
Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024